Table of Content

Scope and Methodology
1.1. Research Methodology
1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary
3.1. Market Snippet by Drug Type
3.2. Market Snippet by Distribution Channel
3.3. Market Snippet by Region

4. Market Dynamics
4.1. Market impacting factors
4.1.1. Drivers
4.1.1.1. The prevalence of orthopedic cases will drive the market growth.
4.1.1.2. Technological advancements in digital X-ray devices
4.1.2. Restraints
4.1.2.1. Risk of adverse effects from radiation exposure
4.1.3. Opportunities
4.2. Impact analysis

5. Industry Analysis
5.1. Porter’s five forces analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis

6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Drug Type
7.1. Introduction
7.1.1. Market size analysis, and y-o-y growth analysis (%), By Drug Type Segment
7.1.2. Market attractiveness index, By Drug Type Segment
7.2. Disease-modifying antirheumatic drug*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
7.2.3. Sulfasalazine
7.2.4. Leflunomide
7.2.5. Methotrexate
7.2.6. Others
7.3. Nonsteroidal anti-inflammatory drugs
7.3.1. Meloxicam
7.3.2. Naproxen
7.3.2.1. Aleve
7.3.2.2. Naprelan
7.3.2.3. Naprosyn
7.3.3. Others
7.4. Biologics
7.4.1. Abatacept
7.4.2. Adalimumab
7.4.3. Etanercept
7.4.4. Infliximab
7.4.5. Rituximab
7.4.6. Tocilizumab
7.4.7. Others
7.5. Corticosteroids
7.6. Others

8. By Distribution Channel
8.1. Introduction
8.1.1. Market size analysis, and y-o-y growth analysis (%), By Distribution Channel Segment
8.1.2. Market attractiveness index, By Distribution Channel Segment
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
8.3. Retail Pharmacies
8.4. Online Pharmacies
8.5. Others

9. By Region
9.1. Introduction
9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key region-specific dynamics
9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type
9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. South America
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type
9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
9.3.5.1. Brazil
9.3.5.2. Argentina
9.3.5.3. Rest of South America
9.4. Europe
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type
9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
9.4.5.1. Germany
9.4.5.2. U.K.
9.4.5.3. France
9.4.5.4. Spain
9.4.5.5. Italy
9.4.5.6. Rest of Europe
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type
9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type
9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape
10.1. Competitive scenario
10.2. Competitor strategy analysis
10.3. Market positioning/share analysis
10.4. Mergers and acquisitions analysis

11. Company Profiles
11.1. Pfizer Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. Biocon Ltd.
11.3. Coherus BioSciences Inc.
11.4. Livzon Pharmaceutical Group Inc.
11.5. Momenta Pharmaceuticals Inc.
11.6. Mycenax Biotech Inc.
11.7. Oncobiologics Inc.
11.8. Oncodesign SA
11.9. Panacea Biotec Ltd.
11.10. Regeneron Pharmaceuticals Inc.
11.11. Sandoz International GmbH
11.12. UCB SA List not Exhaustive*

12. DataM
12.1. Appendix
12.2. About us and services
12.3. Contact us